vs
Side-by-side financial comparison of Cintas (CTAS) and Solventum (SOLV). Click either name above to swap in a different company.
Cintas is the larger business by last-quarter revenue ($6.4B vs $2.0B, roughly 3.2× Solventum). Cintas runs the higher net margin — 7.8% vs 0.6%, a 7.2% gap on every dollar of revenue. On growth, Cintas posted the faster year-over-year revenue change (8.9% vs -3.0%). Cintas produced more free cash flow last quarter ($1.3B vs $-273.0M). Over the past eight quarters, Cintas's revenue compounded faster (61.2% CAGR vs -1.8%).
Cintas Corporation is an American corporation headquartered in Mason, Ohio, which provides a range of products and services to businesses including uniforms, mats, mops, cleaning and restroom supplies, first aid and safety products, fire extinguishers and testing, and safety courses. Cintas is a publicly held company traded on the Nasdaq Global Select Market under the symbol CTAS and is a component of the S&P 500 Index.
Solventum Corporation is an American health care company that was spun off from 3M on April 1, 2024.
CTAS vs SOLV — Head-to-Head
Income Statement — Q4 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $6.4B | $2.0B |
| Net Profit | $502.5M | $13.0M |
| Gross Margin | 83.1% | 54.7% |
| Operating Margin | 10.3% | 4.0% |
| Net Margin | 7.8% | 0.6% |
| Revenue YoY | 8.9% | -3.0% |
| Net Profit YoY | 8.4% | — |
| EPS (diluted) | $1.24 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $6.4B | $2.0B | ||
| Q4 25 | $2.8B | $2.0B | ||
| Q3 25 | $2.7B | $2.1B | ||
| Q2 25 | $2.7B | $2.2B | ||
| Q1 25 | $2.6B | $2.1B | ||
| Q4 24 | $2.6B | $2.1B | ||
| Q3 24 | $2.5B | $2.1B | ||
| Q2 24 | $2.5B | $2.1B |
| Q1 26 | $502.5M | $13.0M | ||
| Q4 25 | $495.3M | $63.0M | ||
| Q3 25 | $491.1M | $1.3B | ||
| Q2 25 | $448.3M | $90.0M | ||
| Q1 25 | $463.5M | $137.0M | ||
| Q4 24 | $448.5M | $31.0M | ||
| Q3 24 | $452.0M | $122.0M | ||
| Q2 24 | $414.3M | $89.0M |
| Q1 26 | 83.1% | 54.7% | ||
| Q4 25 | 50.4% | 51.4% | ||
| Q3 25 | 50.3% | 54.2% | ||
| Q2 25 | 49.7% | 54.4% | ||
| Q1 25 | 50.6% | 53.8% | ||
| Q4 24 | 49.8% | 53.9% | ||
| Q3 24 | 50.1% | 56.0% | ||
| Q2 24 | — | 54.6% |
| Q1 26 | 10.3% | 4.0% | ||
| Q4 25 | 23.4% | 6.3% | ||
| Q3 25 | 22.7% | 80.6% | ||
| Q2 25 | 22.4% | 9.9% | ||
| Q1 25 | 23.4% | 7.3% | ||
| Q4 24 | 23.1% | 6.6% | ||
| Q3 24 | 22.4% | 13.2% | ||
| Q2 24 | 22.2% | 11.7% |
| Q1 26 | 7.8% | 0.6% | ||
| Q4 25 | 17.7% | 3.2% | ||
| Q3 25 | 18.1% | 60.4% | ||
| Q2 25 | 16.8% | 4.2% | ||
| Q1 25 | 17.8% | 6.6% | ||
| Q4 24 | 17.5% | 1.5% | ||
| Q3 24 | 18.1% | 5.9% | ||
| Q2 24 | 16.8% | 4.3% |
| Q1 26 | $1.24 | $0.07 | ||
| Q4 25 | $1.21 | $0.37 | ||
| Q3 25 | $1.20 | $7.22 | ||
| Q2 25 | $1.08 | $0.51 | ||
| Q1 25 | $1.13 | $0.78 | ||
| Q4 24 | $1.09 | $0.18 | ||
| Q3 24 | $1.10 | $0.70 | ||
| Q2 24 | $4.00 | $0.51 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $183.2M | $561.0M |
| Total DebtLower is stronger | — | $4.6B |
| Stockholders' EquityBook value | $4.8B | $5.0B |
| Total Assets | — | $14.1B |
| Debt / EquityLower = less leverage | — | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $183.2M | $561.0M | ||
| Q4 25 | $200.8M | $878.0M | ||
| Q3 25 | $138.1M | $1.6B | ||
| Q2 25 | $264.0M | $492.0M | ||
| Q1 25 | $243.4M | $534.0M | ||
| Q4 24 | $122.4M | $762.0M | ||
| Q3 24 | $101.4M | $772.0M | ||
| Q2 24 | $342.0M | $897.0M |
| Q1 26 | — | $4.6B | ||
| Q4 25 | $2.4B | $5.0B | ||
| Q3 25 | $2.4B | $5.1B | ||
| Q2 25 | $2.4B | $7.8B | ||
| Q1 25 | $2.0B | $7.9B | ||
| Q4 24 | $2.0B | $8.0B | ||
| Q3 24 | $2.0B | $8.1B | ||
| Q2 24 | $2.0B | $8.3B |
| Q1 26 | $4.8B | $5.0B | ||
| Q4 25 | $4.5B | $5.0B | ||
| Q3 25 | $4.8B | $5.0B | ||
| Q2 25 | $4.7B | $3.6B | ||
| Q1 25 | $4.6B | $3.3B | ||
| Q4 24 | $4.3B | $3.0B | ||
| Q3 24 | $4.0B | $3.2B | ||
| Q2 24 | $4.3B | $2.9B |
| Q1 26 | — | $14.1B | ||
| Q4 25 | $10.1B | $14.3B | ||
| Q3 25 | $9.8B | $14.0B | ||
| Q2 25 | $9.8B | $15.1B | ||
| Q1 25 | $9.6B | $14.5B | ||
| Q4 24 | $9.4B | $14.5B | ||
| Q3 24 | $9.1B | $14.7B | ||
| Q2 24 | $9.2B | $14.6B |
| Q1 26 | — | 0.92× | ||
| Q4 25 | 0.54× | 1.00× | ||
| Q3 25 | 0.51× | 1.03× | ||
| Q2 25 | 0.52× | 2.14× | ||
| Q1 25 | 0.44× | 2.43× | ||
| Q4 24 | 0.47× | 2.71× | ||
| Q3 24 | 0.50× | 2.54× | ||
| Q2 24 | 0.47× | 2.90× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.6B | — |
| Free Cash FlowOCF − Capex | $1.3B | $-273.0M |
| FCF MarginFCF / Revenue | 19.7% | -13.6% |
| Capex IntensityCapex / Revenue | 4.7% | — |
| Cash ConversionOCF / Net Profit | 3.12× | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.5B | $-203.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.6B | — | ||
| Q4 25 | $531.2M | $95.0M | ||
| Q3 25 | $414.5M | $76.0M | ||
| Q2 25 | $635.7M | $169.0M | ||
| Q1 25 | $622.0M | $29.0M | ||
| Q4 24 | $441.4M | $219.0M | ||
| Q3 24 | $466.7M | $169.0M | ||
| Q2 24 | $693.0M | $355.0M |
| Q1 26 | $1.3B | $-273.0M | ||
| Q4 25 | $425.0M | $32.0M | ||
| Q3 25 | $312.5M | $-21.0M | ||
| Q2 25 | $521.1M | $59.0M | ||
| Q1 25 | $522.1M | $-80.0M | ||
| Q4 24 | $340.0M | $92.0M | ||
| Q3 24 | $373.8M | $76.0M | ||
| Q2 24 | $591.1M | $297.0M |
| Q1 26 | 19.7% | -13.6% | ||
| Q4 25 | 15.2% | 1.6% | ||
| Q3 25 | 11.5% | -1.0% | ||
| Q2 25 | 19.5% | 2.7% | ||
| Q1 25 | 20.0% | -3.9% | ||
| Q4 24 | 13.3% | 4.4% | ||
| Q3 24 | 14.9% | 3.7% | ||
| Q2 24 | 23.9% | 14.3% |
| Q1 26 | 4.7% | — | ||
| Q4 25 | 3.8% | 3.2% | ||
| Q3 25 | 3.8% | 4.6% | ||
| Q2 25 | 4.3% | 5.1% | ||
| Q1 25 | 3.8% | 5.3% | ||
| Q4 24 | 4.0% | 6.1% | ||
| Q3 24 | 3.7% | 4.5% | ||
| Q2 24 | 4.1% | 2.8% |
| Q1 26 | 3.12× | — | ||
| Q4 25 | 1.07× | 1.51× | ||
| Q3 25 | 0.84× | 0.06× | ||
| Q2 25 | 1.42× | 1.88× | ||
| Q1 25 | 1.34× | 0.21× | ||
| Q4 24 | 0.98× | 7.06× | ||
| Q3 24 | 1.03× | 1.39× | ||
| Q2 24 | 1.67× | 3.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTAS
Segment breakdown not available.
SOLV
| Infection Prevention and Surgical Solutions | $737.0M | 37% |
| Advanced Wound Care | $497.0M | 25% |
| Dental Solutions | $354.0M | 18% |
| Health Information Systems | $342.0M | 17% |
| All Other 4 | $76.0M | 4% |
